Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

642
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
642
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Vaccines01:30

Cancer Vaccines

492
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
492

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.

Cancer medicine·2024
Same author

Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

The Correlation Between Low-Dose Radiotherapy Area of the Mediastinum and CD8+T Cells and the Efficacy of Radiotherapy for Non-Small Cell Lung Cancer.

Cancer management and research·2024
Same author

The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer.

Technology in cancer research & treatment·2022
Same author

Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity.

Science translational medicine·2021

Related Experiment Video

Updated: Aug 26, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Neoadjuvant Immunotherapy Improves Treatment for Early Resectable Non-Small-Cell Lung Cancer: A Systematic Review and

Peng Dong1, Yu Yan1, Liyuan Yang1

  • 1Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Taian, Shandong, China.

Journal of Oncology
|October 10, 2022
PubMed
Summary

Neoadjuvant immunotherapy offers superior efficacy and safety for resectable non-small-cell lung cancer (NSCLC) compared to chemotherapy. This approach demonstrates higher pathological response rates and fewer treatment-related adverse events, making it a promising option for NSCLC patients.

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Related Experiment Videos

Last Updated: Aug 26, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Surgery

Background:

  • Immunotherapy has emerged as a more effective and less toxic treatment option than chemotherapy for advanced non-small-cell lung cancer (NSCLC).
  • Neoadjuvant therapy, administered before surgery, is increasingly explored to improve outcomes in resectable NSCLC.

Purpose of the Study:

  • To evaluate the safety and efficacy of neoadjuvant immunotherapy for patients with resectable non-small-cell lung cancer.
  • To compare the outcomes of neoadjuvant immunotherapy with neoadjuvant chemotherapy in this patient population.

Main Methods:

  • A meta-analysis was conducted using data from eighteen studies, including 678 patients with resectable NSCLC.
  • Literature searches were performed in PubMed, Cochrane Library, and Embase.
  • Efficacy was assessed by pathological complete response (pCR) and major pathological response (MPR); safety was evaluated by treatment-related adverse events (TRAE), surgical resection rate, surgical delay, and complication rates.

Main Results:

  • Neoadjuvant immunotherapy demonstrated significantly higher MPR (ES=0.44) and pCR (ES=0.22) rates compared to neoadjuvant chemotherapy.
  • The incidence of TRAE (ES=0.4), surgical complications (ES=0.24), and surgical delay (ES=0.04) were significantly lower with neoadjuvant immunotherapy.
  • The surgical resection rate was high at 89% with neoadjuvant immunotherapy, comparable to chemotherapy.

Conclusions:

  • Neoadjuvant immunotherapy is a safe and effective treatment strategy for patients with resectable non-small-cell lung cancer.
  • It offers improved pathological response rates and a favorable safety profile compared to neoadjuvant chemotherapy.